Vertex/NHS England Orkambi Talks Plod On
Executive Summary
Talks between NHS England and Vertex over cystic fibrosis drug Orkambi are yet to bear fruit, but further discussions could take place next week.
You may also be interested in...
No Orkambi Deal Yet For England, But Vertex’ Portfolio Approach Still On The Table
Dialogue between Vertex and NHS England over cystic fibrosis drug Orkambi are set to continue after productive talks on April 25.
Pressure Rises On Vertex and NHS England To Reach Orkambi Deal As Parliamentary Scrutiny Increases
Vertex and NHS England are under pressure to strike a deal on cystic fibrosis drug Orkambi after UK a parliamentary debate put health technology appraisal body NICE under the spotlight.
Vertex Commits To Novel Reimbursement Plan For Orkambi In UK, Despite Setback
Despite an initial rejection from NHS England, Vertex remains committed to bringing its novel reimbursement plan to England to secure access to its cystic fibrosis drug, Orkambi.